David Ricks said drugs like Mounjaro and Zepbound are priced to reflect the costs involved, patent expiry, and the enormous ...

Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration said on Friday.

The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.

The big pharma sector is one that’s generally fallen out of favor for many investors over the past few decades, as large ...

A new generation of anti-obesity drugs aims for greater effectiveness, fewer side effects, and more convenience.

The FDA has removed semaglutide from its drug shortage list after the agency determined the current supply of the drug can ...

Prescriptions of obesity management drugs (OMDs) have increased, and these increasing trends are associated with online search trends.

The shortage of Novo Nordisk’s (NVO) blockbuster diabetes and weight-loss drugs is officially over, according to the U.S.

Sky-high demand, a high price tag and tight supplies have created opportunities for bad actors to take advantage of consumers ...

JPMorgan is sticking with Eli Lilly (LLY) as its top biopharma pick for 2025, while also highlighting Gilead Sciences (GILD) ...